This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

Although Eli Lilly (NYSE: LLY) is a leader in the GLP-1 space, the drugmaker continues to develop new and potentially better treatments for people to lose weight. Not everyone has success with GLP-1 drugs or can effectively tolerate them. Recently, the company released trial results that suggested a combination treatment involving tirzepatide (the active ingredient in Zepbound), along with another drug, resulted in even greater weight loss.